AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05562167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
Trial: NCT06420388
Drug: Standard Postoperative Analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous
Trial: NCT05061420
Drug: SAR444245 (Thor-707)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion
Trial: NCT06729047
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive placebo (normal saline)
Trial: NCT06729047
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive ketorolac (0.5 mg/kg)
Trial: NCT06729034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice daily
Trial: NCT04745104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered through IV infusion
Trial: NCT05746208
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01446120
Drug: Insulin loaded Orally Dissolved Films (insulin-ODF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05719896
Drug: DT01 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject was given orally 3 DT01 tablets/day for 8 weeks
Trial: NCT05719896
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject was given orally 3 DT01 tablets/day for 8 weeks
Trial: NCT05719896
Drug: DT01-Placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
Trial: NCT06455735
Drug: 68Ga-FAPI/18F-FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Trial: NCT06253078
Drug: Ciprofol dose 0.4mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of ciprofol was 0.4mg/Kg for induction in this group.
Trial: NCT06253078
Drug: Ciprofol dose 0.3mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of ciprofol was 0.3mg/Kg for induction in this group.
Trial: NCT06253078
Drug: Ciprofol dose 0.2mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of ciprofol was 0.2mg/Kg for induction in this group.
Trial: NCT06030804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Trial: NCT05042908
Drug: LBL-003 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBL-003 was given every two weeks for treatment
Trial: NCT05776043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 3 months
Trial: NCT05009953
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
Trial: NCT05009953
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
Trial: NCT05588531
Drug: Group 1:YK-1169
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
Trial: NCT05588531
Drug: Group 2:YK-1169/Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
Trial: NCT05588531
Drug: Group 3:YK-1169/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Trial: NCT05588531
Drug: Group 4:YK-1169/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Trial: NCT05588531
Drug: Group 5:YK-1169/Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
Trial: NCT06151808
Drug: XTR006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
Trial: NCT00002192
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002192
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03523156
Drug: Azithromycin mass treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
Trial: NCT03523156
Drug: Azithromycin targeted treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
Trial: NCT05970289
Drug: BRII-835
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRII-835 will be given via subcutaneous injection
Trial: NCT05861830
Drug: Chemotherapy selected by the physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy regimen is chosen by the clinical physician and may include, but is not limited to, the following options: the combination of paclitaxel and capecitabine, the combination of paclitaxel and carboplatin, single-agent capecitabine, single-agent platinum drugs, and the combination of gemcitabine and platinum-based chemotherapy. Each treatment cycle consists of a 21-day duration.
Trial: NCT04859569
Drug: LY01011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Trial: NCT04859569
Drug: Xgeva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Trial: NCT06213415
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids plus intratympanic injection
Trial: NCT05103241
Drug: [14C] GP681
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg suspension containing 100μCi of \[14C\]GP681
Trial: NCT05758896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
Trial: NCT05084859
Drug: SM08502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM08502 to be administered orally.
Trial: NCT05084859
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI Protocol to be administered intravenously.
Trial: NCT05985785
Drug: Corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard of treatment for OA of the knee is corticosteroid injection.
Trial: NCT05816226
Drug: Hydrocortisone 2.5%
RxNorm normalized name: HYDROCORTISONE 2.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied four times daily to TMJ with arthralgia
Trial: NCT05816226
Drug: Diclofenac 1% topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied four times daily to TMJ with arthralgia
Trial: NCT04702698
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
Trial: NCT04702698
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
Trial: NCT04550338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of blinded medications
Trial: NCT06392516
Drug: Ketoacid
RxNorm normalized name: Alpha-ketoacid carboxylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml ketoacid two hours before the hemodialysis session ended
Trial: NCT05041010
Drug: Neu2000KWL group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
Trial: NCT05041010
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
Trial: NCT06301789
Drug: Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
Trial: NCT05271721
Drug: epidural transforaminal injection of magnesuim sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transforaminal fluroscopic guided
Trial: NCT05218070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml Saline (0.9%)
Trial: NCT05626309
Drug: Qizhu Yuling Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
Trial: NCT05626309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
Trial: NCT06500793
Drug: PF614 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF614 capsules (25-100 mg)
Trial: NCT05215665
Drug: GEMOX Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
Trial: NCT04854824
Drug: Recommended treatment schedule
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Trial: NCT04854824
Drug: Control treatment schedule
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimens different from the recommended one according to family physician personal practice
Trial: NCT05210439
Drug: Short-treatment of any active antibiotic regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of any active antibiotic treatment for BSI-PA
Trial: NCT05210439
Drug: Long-treatment of any active antibiotic regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of any active antibiotic treatment for BSI-PA
Trial: NCT05798715
Drug: Gleptomet 50/1000(Metformin HCl & Sitagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT05798715
Drug: Janumet 50/1000(Metformin HCl & Sitagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug
Trial: NCT00000363
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06085521
Drug: LNK01001 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally
Trial: NCT06085521
Drug: LNK01001 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally
Trial: NCT06085521
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally
Trial: NCT05208996
Drug: siCoV/KK46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg.
Trial: NCT06717672
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline used is an iv fluid given for fluid replacement
Trial: NCT04823897
Drug: CCI-001
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase.
Trial: NCT04849728
Drug: IVA337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Trial: NCT06331663
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) \> 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
Trial: NCT04849728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Trial: NCT05798793
Drug: TP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
Trial: NCT06729840
Drug: Injection
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D , botox , tramcinolone intralesionally injected in keloid
Trial: NCT05470049
Drug: SHR8554 Injection and SHR0410 Injection
RxNorm normalized name: INFLAMMATION AND INFECTION DETECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
Trial: NCT05470049
Drug: SHR8554 Injection and SHR0410 Injection
RxNorm normalized name: INFLAMMATION AND INFECTION DETECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
Trial: NCT05470049
Drug: SHR8554 Injection and Placebo for SHR0410 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
Trial: NCT06310811
Drug: RD06-04 Cells injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be treated with RD06-04 cells when enrolled in the study
Trial: NCT05807529
Drug: 2ccPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29
Trial: NCT05807529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29
Trial: NCT00442273
Drug: Umbilical cord serum eyedrops
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06334549
Drug: Norepinephrine-P
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after induction of anesthesia, use total intravenous anesthesia maintained with propofol
Trial: NCT06334549
Drug: Norepinephrine-S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
Trial: NCT05042817
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9%
Trial: NCT05042817
Drug: 50 mg prilocaine + 2.5 mcg sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg prilocaine + 2.5 mcg sufentanil
Trial: NCT04846309
Drug: FMISO PET CT
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic.
Trial: NCT03219450
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
Trial: NCT04535427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Trial: NCT05323214
Drug: Control Analgesic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
Trial: NCT05323214
Drug: Fentanyl Analgesic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia